ZYBERNO
Stock Report
Updated Sep 1, 2026

KAIROS PHARMA, LTD. (KAPA)

Healthcare • NYSE

$1.62

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
KAIROS PHARMA, LTD. (KAPA) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-98.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-244.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

KAIROS PHARMA, LTD. (KAPA) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.62
Market Cap:$34.70M

Valuation Multiples (2)

P/B Ratio:8.28x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$32.34M

Price Action & Momentum (3)

Momentum Percentile:10 / 100
% of 52-Week High:76.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-93.6%
Reinvestment Rate:3.6%
Fundamental Growth Rate (g):-8.7%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$82.11
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:11.98x
Quick Ratio:11.98x
Cash Ratio:9.91x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x
Debt-to-Equity Ratio:0.03x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-88.44x
Times Interest Earned:-88.44

Capital Structure (4)

Working Capital:2,909,000.00
Cash And Cash Equivalents:2,626,000.00
Long Term Debt:$0.00
Net Debt:-$2.36M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$5.96M

Bottom Line Performance (3)

-$5.81M
Income Before Tax:$0.00
Ebitda Ttm:-5,797,000.00

Operating Expenses (5)

Operating Expenses:5,957,000.00
R And D Expense:2,449,000.00
Sga Expense:3,508,000.00
Income Tax Expense:$0.00
Interest Expense:63,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$4.46M
Current Assets:$3.17M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$191.00K

Liability Structure (4)

Total Liabilities:265,000.00
Current Liabilities:265,000.00
Long Term Debt:$0.00
Short Term Debt:$265.00K

Equity & Capital (3)

Equity:$4.19M
Retained Earnings:-$17.30M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:265,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$3.76M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$220.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:160,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.28
-$0.28
Earnings Per Share Ttm:-$0.27

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.16

Book Value & Capital (2)

Book Value Per Share:$0.20
Cash Per Share:0.12

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:3.6%
Fundamental Growth Rate (g):-8.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):7.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:KAPA
Company Name:KAIROS PHARMA, LTD.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:21.42M
Shares Outstanding Basic:21.42M
Shares Outstanding Diluted:21.42M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 15:57:29 UTC
Data Timestamp:2026-08-21T18:02:47.129864
Scroll to Top